Navigation Links
Dynatronics Begins Shipping New V-Force Vibration Therapy Units
Date:6/24/2009

SALT LAKE CITY, June 24 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) announced it has begun shipping its new V-Force Vibration Therapy units to customers. These new units employ powerful, whole-body vibration technology, which provides neuromuscular training to increase strength, improve balance and enhance flexibility.

Originally developed for the Russian space program to compensate for bone and muscle loss resulting from extended periods in space, whole-body vibration therapy has been the subject of extensive research for many years. Numerous clinical studies indicate effectiveness in the areas of balance/fall prevention, circulation, knee rehabilitation, low back pain, range of motion and a host of other neuromuscular conditions.

"The V-Force technology represents something totally new and unique in our market," stated Larry K. Beardall, executive vice president of sales and marketing. "We've spent the last three months providing demos and training for our distribution channels. They are now ready to launch this new product to the market."

Initial demand for the new V-Force unit has been strong. "We have a sizable waiting list for units and expect it will take several months before production is able to catch up to demand," said Beardall. "In fact, we expect to sell over $500,000 of this product within the first two weeks of its introduction as we attempt to fill the pipeline and satisfy initial demand."

"V-Force is not just an upgrade of existing technology," added Kelvyn H. Cullimore, Jr, Dynatronics' chairman and president. "It represents a new therapeutic modality. The last time we introduced a new modality was light therapy several years ago that resulted in significant improvement in sales."

"Despite challenging general economic conditions," continued Cullimore, "there are many factors pointing to improved performance for Dynatronics including V-force sales, increasing medical supplies business and greater realization of overall cost savings generated over the past few months with the help of Vici Capital. These improvements contribute to very positive momentum for the Company that we believe will accelerate as the general economy begins to improve."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Actual results may vary from the views expressed in the forward-looking statements contained in this release. Forward-looking statements in this press release include, among others, the statement that the company expects to sell $500,000 of the new product in the first two weeks of its launch and the expectation that the launch of the new product and changes from the company's project with Vici Capital will lead to accelerating positive momentum, based on indications of interest and references to the implementation and expected impact of cost-saving measures in future periods. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, its most recent annual report on Form 10-KSB for the year ended June 30, 2008, and its subsequent quarterly reports on Form 10-Q.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dynatronics Reports Significant Improvement in Operations
2. Dynatronics to Release Third Quarter Results Thursday, May 14, 2009; Conference Call set for 1:30 p.m. ET
3. NASDAQ Gives Dynatronics a Third Three-Month Extension for Minimum Bid Price Compliance
4. Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results
5. Dynatronics to Release Second Quarter Results Friday, February 13, 2009; Conference Call set for 1:00 p.m. ET
6. NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
7. Dynatronics Announces Changes to Board and Launches Operational Improvement Process
8. Dynatronics to Release First Quarter Results Friday, November 14, 2008; Conference Call Set for 1:30 p.m. ET
9. Dynatronics Announces Fiscal Year 2008 Operating Results
10. Dynatronics to Release Fourth Quarter and Year-end Results Monday, September 29, 2008; Conference Call Set for 3:00 p.m. ET
11. Dynatronics Elects Mark A. Crockett to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies are held ... with process innovation in drug formulation and manufacturing. CoreRx offers its clients ... equipment in support of their development and manufacturing goals. , The company ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency ... Series, Outliers in Writing, set to publish in summer 2017. , Dr. Bobrow, ... University of Arizona College of Medicine. He also serves as Medical Director for the ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology: